Hello everyone, I hope you're having a productive week.
I've been tasked with leading the evaluation for a new literature mapping and discovery tool for our 200-person pharmaceutical R&D division. We're a mixed group of bench scientists, clinical researchers, and computational biologists. Our primary pain points are staying on top of emerging competitive intelligence, avoiding blind spots in our therapeutic area landscapes, and efficiently onboarding new team members into complex, decades-long research threads.
After an initial scan, **Iris.ai** and **Research Rabbit** have emerged as the top contenders. I'm looking for detailed, practical comparisons from this community, especially from those in similarly structured, regulated environments.
Here’s a breakdown of our core needs and where I’m hoping for your experiences:
* **Collaboration & Access Management:** With 200 users, we need robust SSO (likely via Azure AD), clear user role definitions (viewer/editor/admin), and the ability to create shared project spaces. Can both tools handle this scale elegantly?
* **Workflow Integration:** Our scientists live in a universe of reference managers (EndNote, Zotero), data visualization tools, and internal knowledge bases. How flexible are the export and integration capabilities? For instance, can you easily push a refined literature set into a shared team repository or a CRM like Veeva for KOL tracking?
* **Search Methodology & Transparency:** The "black box" concern is real in pharma. We need to audit and justify our search strategies for internal reviews. Does one platform offer more transparent or customizable query logic than the other? How do their citation mapping networks compare in terms of explainability?
* **Data Security & Compliance:** This is non-negotiable. We need assurances on data residency, encryption, and how our proprietary search queries and uploaded documents are handled. Any insights here would be invaluable.
* **The Human Element:** The learning curve for a diverse group is a major factor. Which tool required less training for non-power users to get tangible value? Were there specific features that teams adopted faster than others?
I’m particularly interested in any "day-in-the-life" workflow examples. For example, starting with a novel compound's mechanism, mapping out related adverse event literature, and then sharing that dynamic map with the clinical safety team.
We have demos scheduled, but real-world, gritty feedback on pitfalls, unexpected benefits, or total deal-breakers will help us ask the right questions. Thank you in advance for sharing your wisdom—it will directly impact a lot of researchers here.
Stay connected